Improving digestive capabilities in nutritionally compromised patients with CF

Volume 5, Issue 6.

In this issue Dr. Steven Freedman, Professor of Medicine from Harvard Medical School discusses digestive capabilities in nutritionally compromised patients with CF. Listen in as Dr. Freedman explains the importance of pancreatic enzyme replacement and present patient scenarios and best practices of treatment.

P. aeruginosa eradication and reinfection

Volume 5, Issue 4.

In this issue of eCysticfibrosis Review Dr. Ratjen discusses the challenges of P. aeruginosa eradication. He explains the importance to treat early and available treatment options. He also addresses whether treatment should be repeated in patients who develop recurrence of infection and how to handle patients failing eradication therapy.

Pulmonary exacerbations: diagnoses, and therapeutic regimens

Volume 5, Issue 2.

In this podcast Dr. Patrick Flume, Professor of Medicine and Pediatrics at the Medical University of South Carolina in Charleston, discusses pulmonary exacerbation. He provides patient case scenarios to understand the importance of pulmonary exacerbation and the ability to identify when it occurs.

What Does CFTR Tell Us About Lung Disease?

Volume 4, Issue 12.

In this issue our guest author is Dr. Patrick Sosnay, Assistant Professor at the Johns Hopkins Cystic Fibrosis Center. Dr. Sosnay will illustrate how the genetics of CF can be used to make a diagnosis or identify a CF carrier, predict how individuals with a given mutation will do clinically and allow clinicians to select currently available and hopefully future therapies that directly address the defect caused by their individual CFTR mutations.

Behavioral Treatment to Improve Dietary Adherence and Weight Gain in Children with Cystic Fibrosis

Volume 4, Issue 10.

In this podcast we have guest author Lori Stark, PhD, ABPP, Professor of Pediatrics at the University of Cincinnati College of Medicine. Dr. Stark, discusses how to use “shaping” to encourage a child to eat a non-preferred food, describes the role of “attention” in maintaining behaviors incompatible with eating, and discusses the use of caloric goal-setting and dietary tracking applications to monitor treatment progress.

Highlights of the 27th Annual North American Cystic Fibrosis Conference

Special Edition 2014 – Steven Rowe.

In this special edition of eCysticFibrosis Review, Dr. Peter Mogayzel discusses data findings from Dr. Steven Rowe results of the G551D observational study presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah.

Highlights of the 27th Annual North American Cystic Fibrosis Conference

Special Edition 2014 – Scott Powers.

In this special edition of eCysticFibrosis Review, Dr. Peter Mogayzel discusses findings from Dr. Scott Powers clinical trial on Behavioral & Nutrition Treatment for Preschoolers With CF which he presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah.

Highlights of the 27th Annual North American Cystic Fibrosis Conference

Special Edition 2014 – Elizabeth Yen.

In this special edition of eCysticFibrosis Review, Dr. Peter Mogayzel discusses outcomes presented by Dr. Elizabeth during her presentation on Nutritional Status and Outcomes in Pediatrics CF presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah.

Highlights of the 27th Annual North American Cystic Fibrosis Conference

Special Edition 2014 – Kenneth Olivier.

In this special edition of eCystic Fibrosis review, Dr. Peter Mogayzel discusses highlights from Dr. Kenneth Olivier’s talk on Nontuberculosis Mycobacteria: Updates in CF presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah.

New Therapies in Cystic Fibrosis Directed Toward the Basic Defect

Volume 4, Issue 8.

In this podcast guest author Steven Rowe, MD, Associate Professor of Medicine from the University of Alabama at Birmingham, describes how CFTR modulator therapy fits into the clinical armamentarium of CF lung disease; identifies which patients are most appropriate for CF modulator treatment; and describes current research efforts and how to identify patients suitable for referral for consideration in CFTR modulator clinical trials.